BGT — Bio-Gene Technology Balance Sheet
0.000.00%
Last trade - 00:00- AU$5.86m
- AU$4.77m
- AU$0.43m
Annual balance sheet for Bio-Gene Technology, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | AAS | AAS | AAS | AAS | AAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 3.93 | 6.34 | 2.99 | 2.21 | 1.14 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.524 | 0.438 | 0.446 | 0.524 | 0.472 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 4.66 | 7 | 3.58 | 2.94 | 1.97 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.023 | 0.023 | 0.015 | 0.019 | 0.013 |
| Net Intangible Assets | |||||
| Total Assets | 5 | 7.3 | 3.84 | 3.16 | 2.15 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.593 | 1.01 | 0.574 | 0.346 | 0.51 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 0.755 | 1.03 | 0.614 | 0.368 | 0.523 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 4.25 | 6.27 | 3.22 | 2.79 | 1.63 |
| Total Liabilities & Shareholders' Equity | 5 | 7.3 | 3.84 | 3.16 | 2.15 |
| Total Common Shares Outstanding |